Vera Therapeutics
As expected, Vera Therapeutics (VERA) product Ataticept achieved proteinuria reduction in ORIGIN Phase 3 trials in adults with IgA nephropathy.

This is indeed great news!

The trial met the primary endpoint at week 36.

Ataticept has achieved 46%reduction from baseline and 42%reduction compared to placebo on wek 36.

Vera is not sharing cGFR at this time . . .